Updated - HCV Guidance website

In Case You Missed It

Updated Thursday, April 27, 2017

Guidelines
HCV Guidelines
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.
Homepage - HCV Guidelines

Stay current with all guideline updates, click here.

What’s New and Updates/Changes
This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance.

Global Changes Occurring throughout the document:

• RAV changed to RAS
• Standardized renal function parameter from CrCI to eGFR
   

Initial Treatment:

• Includes new recommendation to shorten the duration of ledipasvir (90 mg)/sofosbuvir (400 mg) in patients without cirrhosis to 8 weeks for non-black, HIV-uninfected, and whose HCV RNA is <6 million IU/mL
• Updated grading of sofosbuvir/velpatasvir for genotypes 5 and 6
• Language added related to recent data regarding 8 weeks of PrOD for genotype 1b with early stage fibrosis
   

Retreatment:

• Updated recommendations in Genotype 3 sections
   

Decompensated:

• Extrapolation of data from patients with compensated cirrhosis to patients with decompensated cirrhosis in genotypes 5 and 6
   

Renal:

• Genotype 1 elbasvir/grazoprevir class rating changed from Class II to Class I
   

Upcoming Updates:

• Guidance will be forthcoming regarding treatment of adolescents living with chronic HCV given recent FDA-approvals